Left atrial strain as a pre-operative prognostic marker for patients with severe mitral regurgitation.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 02 2021
Historique:
received: 02 07 2020
revised: 13 08 2020
accepted: 04 09 2020
pubmed: 14 9 2020
medline: 28 5 2021
entrez: 13 9 2020
Statut: ppublish

Résumé

In patients with severe mitral regurgitation (MR), additional echocardiographic indices could be helpful to optimize surgical timing before irreversible left heart myocardial dysfunction has occurred. We investigated the correlation of left atrial (LA) strain by speckle tracking echocardiography with prognosis after mitral surgery for severe MR, and its association with LA fibrosis. 71 patients with primary severe MR undergoing pre-operative echocardiographic assessment were initially enrolled. Exclusion criteria were: other valvular disease>moderate, history of coronary artery disease, heart failure (HF), hypertrophic cardiomyopathy, left bundle branch block, previous pacemaker implantation, heart transplantation, poor acoustic window. The primary endpoint was the occurrence of composite events (HF and mortality); the secondary endpoint was post-operative functional capacity (NYHA and Borg CR10 class). LA fibrosis was assessed by atrial biopsy specimens in a subset of patients. Of 65 eligible patients, the primary endpoint occurred in 30 patients (medium follow-up: 3.7 ± 1 years for event-group, 6.8 ± 1 years for non-event group). After Kaplan-Meier analysis, peak atrial longitudinal strain (PALS) provided good risk stratification (5-year event-free survival:90 ± 5% for PALS≥21% vs 30 ± 9% for PALS<21%, p < 0.0001); it was an independent and incremental predictor of outcome in four multivariate Cox adjusted models. There was also an association between PALS and the secondary endpoint (NYHA: r Global PALS emerged as a reliable predictor of outcome and functional capacity for severe primary MR, and as a marker of LA fibrosis.

Sections du résumé

BACKGROUND
In patients with severe mitral regurgitation (MR), additional echocardiographic indices could be helpful to optimize surgical timing before irreversible left heart myocardial dysfunction has occurred. We investigated the correlation of left atrial (LA) strain by speckle tracking echocardiography with prognosis after mitral surgery for severe MR, and its association with LA fibrosis.
METHOD
71 patients with primary severe MR undergoing pre-operative echocardiographic assessment were initially enrolled. Exclusion criteria were: other valvular disease>moderate, history of coronary artery disease, heart failure (HF), hypertrophic cardiomyopathy, left bundle branch block, previous pacemaker implantation, heart transplantation, poor acoustic window. The primary endpoint was the occurrence of composite events (HF and mortality); the secondary endpoint was post-operative functional capacity (NYHA and Borg CR10 class). LA fibrosis was assessed by atrial biopsy specimens in a subset of patients.
RESULTS
Of 65 eligible patients, the primary endpoint occurred in 30 patients (medium follow-up: 3.7 ± 1 years for event-group, 6.8 ± 1 years for non-event group). After Kaplan-Meier analysis, peak atrial longitudinal strain (PALS) provided good risk stratification (5-year event-free survival:90 ± 5% for PALS≥21% vs 30 ± 9% for PALS<21%, p < 0.0001); it was an independent and incremental predictor of outcome in four multivariate Cox adjusted models. There was also an association between PALS and the secondary endpoint (NYHA: r
CONCLUSIONS
Global PALS emerged as a reliable predictor of outcome and functional capacity for severe primary MR, and as a marker of LA fibrosis.

Identifiants

pubmed: 32920069
pii: S0167-5273(20)33743-8
doi: 10.1016/j.ijcard.2020.09.009
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

139-145

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Giulia Elena Mandoli (GE)

Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy.

Maria Concetta Pastore (MC)

Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy. Electronic address: pastore2411@gmail.com.

Giovanni Benfari (G)

Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy.

Gianluigi Bisleri (G)

Division of Cardiac Surgery, Queen's University Kingston Health Sciences Centre, Canada.

Massimo Maccherini (M)

Department of Cardiac Surgery, University of Siena, Siena, Italy.

Gianfranco Lisi (G)

Department of Cardiac Surgery, University of Siena, Siena, Italy.

Paolo Cameli (P)

Department of Clinical Medical and Neurosciences, Respiratory Disease and Lung Transplantation Section, Le Scotte Hospital, University of Siena, Italy.

Matteo Lisi (M)

Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy.

Aleksandr Dokollari (A)

Cardiac Surgery, St. Michael Hospital, Toronto, ON, Canada.

Chiara Carrucola (C)

Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy.

Mariangela Vigna (M)

Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy.

Gianfranco Montesi (G)

Department of Cardiac Surgery, University of Siena, Siena, Italy.

Serafina Valente (S)

Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy.

Sergio Mondillo (S)

Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy.

Matteo Cameli (M)

Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH